A New Scoring System for the Evaluation of Ibrutinib-Associated Arrhythmias in Chronic Lymphocytic Leukemia: The ACEF Score

Basit Öğe Kaydı
dc.contributor.authorKoyuncu, Ilhan
dc.contributor.authorKoyuncu, Betuel
dc.contributor.authorUgur, Mehmet Can
dc.contributor.authorKoyun, Emin
dc.contributor.authorSenoz, Oktay
dc.contributor.authorDogdus, Mustafa
dc.contributor.authorBilgir, Oktay
dc.date.accessioned2025-03-20T09:50:27Z
dc.date.available2025-03-20T09:50:27Z
dc.date.issued2024
dc.departmentİzmir Bakırçay Üniversitesi
dc.description.abstractObjective: Bruton tyrosine kinase inhibition in cardiac tissue causes inhibition of the PI3K-AKT signaling pathway, which is responsible for protecting cardiac tissue during stress. Therefore, there is an increase in the risk of arrhythmia. This study explores the prediction of that risk with the Age-Creatinine-Ejection Fraction (ACEF) score as a simple scoring system based on the components of age, creatinine, and ejection fraction. Materials and Methods: Patients diagnosed with chronic lymphocytic leukemia (CLL) and receiving ibrutinib treatment for at least 1 year were evaluated with echocardiography and Holter electrocardiography and the results were compared with a control group of CLL patients who had not received treatment. ACEF score was calculated with the formula age/left ventricular ejection fraction+1 (if creatinine >2.0 mg/dL). Results: When the arrhythmia development of the patients was evaluated, no statistically significant difference was found between the control and ibrutinib groups in terms of types of arrhythmias other than paroxysmal atrial fibrillation (PAF). PAF was found to occur at rates of 8% versus 22% (p=0.042) among ibrutinib non -users versus users. For patients using ibrutinib, an ACEF score of >1.21 predicted the development of PAF with 77% sensitivity and 75% specificity (area under the curve: 0.830, 95% confidence interval: 0.698-0.962, p<0.001). Conclusion: The ACEF score can be used as a risk score that predicts the development of PAF in patients diagnosed with CLL who are scheduled to start ibrutinib.
dc.identifier.doi10.4274/tjh.galenos.2024.2024.0045
dc.identifier.endpage96
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue2
dc.identifier.pmid38721568
dc.identifier.scopus2-s2.0-85195227528
dc.identifier.scopusqualityQ3
dc.identifier.startpage91
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2024.2024.0045
dc.identifier.urihttps://hdl.handle.net/20.500.14034/2203
dc.identifier.volume41
dc.identifier.wosWOS:001245706200002
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.ispartofTurkish Journal of Hematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250319
dc.subjectIbrutinib
dc.subjectACEF score
dc.subjectChronic lymphocytic leukemia
dc.subjectArrhythmia
dc.titleA New Scoring System for the Evaluation of Ibrutinib-Associated Arrhythmias in Chronic Lymphocytic Leukemia: The ACEF Score
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu